JSA advised and represented Multiples Private Equity Fund (“Multiples”) in an investment of INR 685 crores by a consortium of investors led by Multiples for a 9.3% stake in BDR Pharmaceuticals International Private Limited (“BDR Pharma”). This is the first investment into the company.
BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores. The company focuses on therapeutic segments such as oncology and critical care with a growing presence in dermatology and gynaecology. BDR Pharma shot to fame during Covid-19 for developing copies of antivirals such as remdesivir, favipiravir, molnupiravir and lyophilized amphotericin b injection.
JSA team comprised Lead Partner – Anand Lakra, Principal Associate – Niharika Mepani, Senior Associate – Ami Shah and Associate – Jinay Shah and Sonakshi Verma,
JSA Employment team Partner Maneesh Upadhyay and Senior Associate – Ashrafi Ginwalla.
JSA competition team Partner & Head of Practice (Competition Law) – Vaibhav Choukse, Principal Associate – Ela Bali and, Senior Associate – Nripi Jolly.
Anand is an equity partner at JSA’s Mumbai office. His practice includes private and public M&A, private equity, venture capital and capital market transactions, with a particular focus on securities law matters.